January 2021 – Proactive Investors: ReNeuron Group completes first dosing of patients in study for new degenerative eye disease therapy
July 2020 – Proactive Investors: ReNeuron’s Michael Hunt says key focus now is to build dataset for retinal disease study
June 2020 – Proactive Investors: ReNeuron’s Michael Hunt explains new emphasis on its retinal and exosome technology programmes
May 2020 – Proactive Investors: ReNeuron’s Michael Hunt talks new potential for its CTX therapy in treating Huntington’s disease
April 2020 – Proactive Investors: ReNeuron looking at applications of its own technology to deliver virus vaccine
February 2020 – Proactive Investors: ReNeuron’s retinal treatment ‘appears to have sustained long-term beneficial effect’
December 2019 – Proactive Investors: ReNeuron in active on-going talks for further potential out-licence deals
October 2019 – Proactive Investors: ‘All systems go’ for ReNeuron’s retinitis pigmentosa programme as it looks to follow-up studies
Proactive Investors: ReNeuron makes key business development hire as it looks to build on licensing deals
Proactive Investors: “ReNeuron ‘very encouraged’ by positive retinitis pigmentosa study results”